Clinical evaluation of CA72-4 immunoradiometric assay for serum TAG-72 antigen in patients with carcinoma

N. Ohuchi, E. Gero, S. Mori, M. Akimoto, N. Matoba, T. Nishihira, K. Hirayama, D. Colcher, J. Schlom

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


Serum levels of tumor-associated glycoprotein (TAG-72) in patients with carcinoma have been investigated by an immunoradiometric assay (IRMA), CA72-4, utilizing anti-TAG-72 monoclonal antibodies (MoAbs) CC49 and B72.3. The cut-off value for CA72-4 assay was determined as 4.0 units/ml according to the mean+2SD (3.9 units/ml), and only 3% of healthy individuals (n=514) demonstrated elevated levels of TAG-72. The average concentration of serum TAG-72 in cancer patients (n=265) was 37.9 units/ml, much higher than that (2.6 units/ml) in patients without malignancy (n=212). Elevated TAG-72 was found in 48% of patients with gastric carcinoma, 52% with colorectal carcinoma, 46% with pancreatic carcinoma, 37% with breast carcinoma and 60% with ovarian carcinoma. Serum TAG-72 in patients with primary carcinoma was serially measured to determine plasma clearance, and the mean period of decrease to the cut-off value was 23.2 days after removal of the tumors. These results indicate that CA72-4 IRMA may be useful to defect serum TAG-72 antigen in patients with gastrointestinal, breast, ovarian and other epithelial malignancies.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalJournal of Tumor Marker Oncology
Issue number1
Publication statusPublished - 1990
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Clinical evaluation of CA72-4 immunoradiometric assay for serum TAG-72 antigen in patients with carcinoma'. Together they form a unique fingerprint.

Cite this